Latest News and Press Releases

BASEL, Switzerland, Sept. 29, 2006 (PRIMEZONE) -- Data presented at ICAAC further support phase III development program scheduled to start by year-end in invasive candida (yeast) and aspergillus...

BASEL, Switzerland, Aug. 24, 2006 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) reports interim financial results. Three compounds planned to be in phase III by year-end. Highlights of the...

BASEL, Switzerland, June 27, 2006 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) presents data on its antifungal BAL8557 showing a promising safety and drug-drug interaction profile. Additional...

BASEL, Switzerland, May 17, 2006 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today completion of recruitment of over 1000 patients in its BACH study (Benefit of Alitretinoin in...

BASEL, Switzerland, May 17, 2006 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today the initiation of a community-acquired pneumonia trial further expanding the development program...

BASEL, Switzerland, May 2, 2006 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today that it received fast track designation from the U.S. Food and Drug Administration (FDA) for its...

BASEL, Switzerland, March 28, 2006 (PRIMEZONE) -- Basilea's (SWX:BSLN) shareholders approved today the annual report, the 2005 financial statements, as well as the release of the members of the Board...

BASEL, Switzerland, March 2, 2006 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. announces today positive results for its first comparative phase III trial with ceftobiprole. Ceftobiprole showed a high...

BASEL, Switzerland, Feb. 28, 2006 (PRIMEZONE) -- Basilea (SWX:BSLN) announced 2005 financial results reflecting positive operating cash flow. Payments from Basilea's license partner, Johnson &...

BASEL, Switzerland, Dec. 20, 2005 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) presents positive phase II clinical trial data on its water-soluble azole BAL8557 in a late-breaker abstract at...